HOME >> MEDICINE >> NEWS
Study finds drug works against scleroderma lung disease

SAN DIEGO-A drug that suppresses the immune system and reduces inflammation has been shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma, according to results presented at the American Thoracic Society International Conference on May 23.

The study found that a significantly higher proportion of patients taking the drug, cyclophosphamide, showed improvement in lung function compared with those taking a placebo. Patients taking the drug also had significant reductions in breathlessness and reported feeling more energetic and in better health.

"Until now, there has been no proven therapy for scleroderma, and 60-70% of patients die within 10 years," said Donald Tashkin, M.D., Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles, one of the authors of the new study on the drug.

Although previous studies have suggested that cyclophosphamide may benefit people suffering from scleroderma, this study, known as the Scleroderma Lung Study, is the first large, randomized, controlled trial to study the drug's effectiveness against scleroderma lung disease. The study, sponsored by the National Institutes of Health, was conducted at 13 centers throughout the United States.

Scleroderma is a progressive disease that leads to the hardening and tightening of the skin and connective tissues-the fibers that provide the framework and support for the body. The disease can affect the blood vessels and internal organs, and about 80% of patients also have a problem with their lungs that leads to scarring (fibrosis). This scarring is caused by inflammation, in which an abnormal number of white blood cells accumulate in the lungs. The inflammation and scarring make breathing more difficult. More than half of scleroderma deaths are due to lung-related problems, Dr. Tashkin said.

About 150,000 Americans have scleroderma. Three to four time
'"/>

Contact: Jim Augustine
619-525-6216
American Thoracic Society
23-May-2005


Page: 1 2 3

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study finds drug works against scleroderma lung disease

(Date:5/23/2013)... (PRWEB) May 23, 2013 911 Signal USA ... expo will begin on May 22 and run through May ... and information about the company's emergency vehicle lights ... new 2013 Dodge Charger at the expo. , The Charger ... on the market and can be seen by visiting 911 ...
(Date:5/22/2013)... 2013 Most women dread cellulite and ... factors, including estrogen being a factor in the formation ... deposits stored and smashed together which create that dimpling ... take a multi-pronged action," says Kathy Heshelow, founder of ... products like Cellulite Whisperer ® that work to ...
(Date:5/22/2013)... Catalyst Exhibits, Inc., an award-winning global ... its website that allows visitors to view a ... immersive, 360-degree, interactive experience. , The new viewing ... virtually experience the exhibit design Catalyst created for St. ... Users have the ability to interact with the hi-resolution ...
(Date:5/22/2013)... San Francisco, CA (PRWEB) May 22, 2013 ... funerals costing $6,500 or more on average, a funeral concierge ... a funeral, among other benefits. Funeral Financials ... With the average household income in the U.S. ... recession according to Sentier Research, the average funeral costs 12.6% ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 On a ... Lisa, spent a few hours watching “The Bourne Legacy” at ... While this may seem like a typical activity to many ... This little stretch of respite from their everyday reality has ... Seals Serving DC | MD | VA. , Life changed ...
Breaking Medicine News(10 mins):Health News:911 Signal USA Attends the 2013 Southwest Police Fleet Expo 2Health News:Get Cellulite Under Control Now with Cellulite Whisperer® Products Introduced by Sublime Beauty® 2Health News:Catalyst Exhibits Debuts 360 Degree Virtual Tour of St. Jude Medical Trade Show Booth 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3
(Date:5/22/2013)... --  Accuray Incorporated (Nasdaq: ARAY ), ... at the 2013 Jefferies Global Healthcare Conference in ... 2013 at 1:30 p.m. EDT/10:30 a.m. PDT. ... online from the Investor Relations page of the Company,s ... of the presentation will begin approximately one hour after ...
(Date:5/22/2013)... , May 22, 2013 JenaValve Technology, Inc., a ... implantation (TAVI) systems for the treatment of aortic valve disease, ... enaValve Eval U ation of Long Term P erformance ... E vere Ao R tic Stenosis (JUPITER) Registry at EuroPCR ... registry to evaluate five-year long term safety and effectiveness of ...
(Date:5/22/2013)... 22, 2013  The Lupus Research Institute (LRI) today ... new treatments for lupus nephritis, a serious kidney complication ... The conference launched a new international alliance of researchers ... Network (LNTN). More than 50 of the ... together to focus on two critical questions: 1) Which ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2
Cached News: